GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Return-on-Tangible-Asset

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Return-on-Tangible-Asset : 0.83% (As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cosmo Pharmaceuticals NV's annualized Net Income for the quarter that ended in Jun. 2023 was CHF2.9 Mil. Cosmo Pharmaceuticals NV's average total tangible assets for the quarter that ended in Jun. 2023 was CHF350.2 Mil. Therefore, Cosmo Pharmaceuticals NV's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 was 0.83%.

The historical rank and industry rank for Cosmo Pharmaceuticals NV's Return-on-Tangible-Asset or its related term are showing as below:

CHIX:COPNz' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -7.55   Med: 4.33   Max: 73.86
Current: 2.96

During the past 13 years, Cosmo Pharmaceuticals NV's highest Return-on-Tangible-Asset was 73.86%. The lowest was -7.55%. And the median was 4.33%.

CHIX:COPNz's Return-on-Tangible-Asset is ranked better than
54.9% of 1082 companies
in the Drug Manufacturers industry
Industry Median: 1.84 vs CHIX:COPNz: 2.96

Cosmo Pharmaceuticals NV Return-on-Tangible-Asset Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Return-on-Tangible-Asset Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.35 -4.27 -1.43 4.34 4.31

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.10 11.30 4.00 4.95 0.83

Competitive Comparison of Cosmo Pharmaceuticals NV's Return-on-Tangible-Asset

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Pharmaceuticals NV's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Return-on-Tangible-Asset falls into.



Cosmo Pharmaceuticals NV Return-on-Tangible-Asset Calculation

Cosmo Pharmaceuticals NV's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=16.999/( (425.455+363.905)/ 2 )
=16.999/394.68
=4.31 %

Cosmo Pharmaceuticals NV's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=2.9/( (363.905+336.466)/ 2 )
=2.9/350.1855
=0.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2023) net income data.


Cosmo Pharmaceuticals NV  (CHIX:COPNz) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Cosmo Pharmaceuticals NV Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines